Grifols Receives FDA Approval for Plasma-related Facility in Clayton

April 22, 2024

Grifols, a global leader in plasma medicines, on Monday announced it has received approval from the U.S. Food and Drug Administration (FDA) for its new immunoglobulin (Ig) purification and filling facility at its Clayton manufacturing campus, one of the world’s largest sites for producing plasma-derived medicines.